A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

BACKGROUND: NK105 is a novel nanoparticle drug delivery formulation that encapsulates paclitaxel (PTX) in polymeric micelles. We conducted an open-label phase III non-inferiority trial to compare the efficacy and safety of NK105 and PTX in metastatic or recurrent breast cancer. METHODS: Patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yasuhiro, Mukai, Hirofumi, Saeki, Toshiaki, Ro, Jungsil, Lin, Yung-Chang, Nagai, Shigenori E., Lee, Keun Seok, Watanabe, Junichiro, Ohtani, Shoichiro, Kim, Sung Bae, Kuroi, Katsumasa, Tsugawa, Koichiro, Tokuda, Yutaka, Iwata, Hiroji, Park, Yeon Hee, Yang, Youngsen, Nambu, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461876/
https://www.ncbi.nlm.nih.gov/pubmed/30745582
http://dx.doi.org/10.1038/s41416-019-0391-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461876/
https://www.ncbi.nlm.nih.gov/pubmed/30745582
http://dx.doi.org/10.1038/s41416-019-0391-z

Ejemplares similares